John Sourbeer
Stock Analyst at UBS
(0.77)
# 3,960
Out of 4,996 analysts
39
Total ratings
36.84%
Success rate
-17.13%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QGEN Qiagen | Maintains: Neutral | $48 → $50 | $43.90 | +13.90% | 5 | Aug 7, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $285 → $320 | $261.52 | +22.36% | 4 | Jul 25, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $163.79 | +46.53% | 2 | Jul 25, 2025 | |
| CYRX Cryoport | Maintains: Buy | $10 → $11 | $9.20 | +19.57% | 6 | Apr 1, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $25.66 | -8.42% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $28.33 | +58.84% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.21 | +65.29% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $91.69 | +58.14% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $496.79 | -3.38% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $31.04 | +228.61% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $11.72 | +326.62% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $133.55 | -4.16% | 2 | Jul 27, 2022 |
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $48 → $50
Current: $43.90
Upside: +13.90%
West Pharmaceutical Services
Jul 25, 2025
Maintains: Buy
Price Target: $285 → $320
Current: $261.52
Upside: +22.36%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $163.79
Upside: +46.53%
Cryoport
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $11
Current: $9.20
Upside: +19.57%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $25.66
Upside: -8.42%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $28.33
Upside: +58.84%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.21
Upside: +65.29%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $91.69
Upside: +58.14%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $496.79
Upside: -3.38%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $31.04
Upside: +228.61%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $11.72
Upside: +326.62%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $133.55
Upside: -4.16%